stockrowBridgeBio Pharma, Inc. (BBIO) vs Halozyme Therapeutics, Inc. (HALO)
- BridgeBio Pharma, Inc. BBIO 74.30 +0.04%
- Halozyme Therapeutics, Inc. HALO 103.49 −15.83%
BridgeBio Pharma, Inc. and Halozyme Therapeutics, Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. and Halozyme Therapeutics, Inc. are of similar size ($14.5B and $14.0B). BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 29.5×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 167.3% against 45.0%. Halozyme Therapeutics, Inc. has the higher net margin (26.9% vs −62.6%) and the higher return on invested capital (19.9% vs 0.00%). Across the 18 metrics below, Halozyme Therapeutics, Inc. leads on 14 and BridgeBio Pharma, Inc. on 4.
Valuation
Profitability
| Metric | BBIO | HALO | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.34% | 82.27% | 65.16% |
| Operating margin | (38.52%) | 37.41% | 0.00% |
| Net margin | (62.62%) | 26.93% | 0.00% |
| Free cash flow margin | (39.11%) | 49.84% | 0.00% |
| Return on equity | 26.22% | 216.38% | (50.12%) |
| Return on assets | (37.48%) | 17.05% | (45.60%) |
| Return on invested capital | 0.00% | 19.87% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack